A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy. According to the researchers, such a targeted poison could complement antiretroviral therapy, which dramatically reduces the replication of HIV in infected cells but does not eliminate them.
The 40 mice in the experiment were bioengineered to have a human immune system. They were infected with HIV for several months and then given a combination of antiretroviral drugs for four weeks. Half of the animals subsequently received a two-week dose of a genetically designed, HIV-specific poison, or immunotoxin, to complement the antiretrovirals, while the other half continued receiving antiretrovirals alone. The scientists found that, compared to antiretrovirals alone, the addition of the immunotoxin significantly reduced both the number of HIV-infected cells producing the virus in multiple organs and the level of HIV in the blood.
According to the researchers, these findings, coupled with results from previous studies, suggest that treating certain HIV-infected people with a combination of antiretrovirals and an immunotoxin might help achieve sustained disease remission, in which HIV can be controlled or eliminated without a lifetime of antiretroviral therapy. However, further study is required, the scientists write.
The immunotoxin, known as 3B3-PE38, was created in 1998 in the laboratories of Edward A. Berger, Ph.D., of the National Institute of Allergy and Infectious Diseases, and Ira Pastan, Ph.D., of the National Cancer Institute, both part of NIH. This genetically modified bacterial toxin targets HIV-infected cells and becomes internalized by them, shutting down protein synthesis and triggering cell death. The study was designed by Drs. Berger and Pastan in collaboration with J. Victor Garcia, Ph.D., and colleagues at the University of North Carolina School of Medicine, where the experiments were performed.
ARTICLE: PW Denton et al. Targeted cytotoxic therapy kills persisting HIV-infected cells during ART. PLOS Pathogens DOI: ppat.1003872 (2014).
NIAID Director Anthony S. Fauci, M.D., and Edward A. Berger, Ph.D., senior investigator in the NIAID Laboratory of Viral Diseases, are available for comment.
CONTACT: To schedule interviews, please contact Laura S. Leifman, (301) 402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.
NIH...Turning Discovery Into Health®
Newly discovered 'multicomponent' virus can infect animals
26.08.2016 | US Army Medical Research Institute of Infectious Diseases
Symmetry crucial for building key biomaterial collagen in the lab
26.08.2016 | University of Wisconsin-Madison
Scientists and engineers striving to create the next machine-age marvel--whether it be a more aerodynamic rocket, a faster race car, or a higher-efficiency jet...
Waveguides are widely used for filtering, confining, guiding, coupling or splitting beams of visible light. However, creating waveguides that could do the same for X-rays has posed tremendous challenges in fabrication, so they are still only in an early stage of development.
In the latest issue of Acta Crystallographica Section A: Foundations and Advances , Sarah Hoffmann-Urlaub and Tim Salditt report the fabrication and testing of...
Electrochemists at TU Graz have managed to use monocrystalline semiconductor silicon as an active storage electrode in lithium batteries. This enables an integrated power supply to be made for microchips with a rechargeable battery.
Small electrical gadgets, such as mobile phones, tablets or notebooks, are indispensable accompaniments of everyday life. Integrated circuits in the interiors...
Recent findings indicating the possible discovery of a previously unknown subatomic particle may be evidence of a fifth fundamental force of nature, according...
A nanocrystalline material that rapidly makes white light out of blue light has been developed by KAUST researchers.
25.08.2016 | Event News
24.08.2016 | Event News
12.08.2016 | Event News
30.08.2016 | Ecology, The Environment and Conservation
30.08.2016 | Power and Electrical Engineering
30.08.2016 | Life Sciences